NEXTEK-LIMITED
20.10.2021 11:32:06 CEST | Business Wire | Press release
NEXTLOOPP, the groundbreaking project by Nextek Limited, that recently won the overall award for ‘Best Sustainable Packaging Innovation’ at Packaging Europe’s Sustainability Awards - https://packagingeurope.com/sustainability-awards-2021-winners-revealed/ has revealed the results of its highly successful tracer-based sorting trials held at TOMRA (Germany) in September 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005464/en/
The trials, to specifically sort food-grade plastic packaging waste, achieved a resounding 99.9% sorting purity at maximum production speed.
This demonstrates that Nextek’s unique technology efficiently differentiates food packaging from non-food packaging to meet the standards required by the Food Standards Authorities in the UK and EU. Being able to identify and sort any number of pack variants from bleach bottles to milk bottles in any plastic type is a world-first that will transform the way we recycle the prolific volume of single-use post-consumer food packaging waste back into circular applications.
This announcement marks 12 months of NEXTLOOPP’s programme to close the loop on food-grade Polypropylene (FGPP), which is the biggest plastic fraction in the FMCG sector. In the UK alone, 210,000 tonnes of FGPP packaging is used in pots, tubs, trays and films each year, and this cutting-edge innovation creates the opportunity to recycle Polypropylene (PP) back into food packaging.
This also heralds a new era in the plastics packaging recycling industry and the validation of NEXTLOOPP’s PolyPRISMTM ‘plug-and-play’ marker system, as used on TOMRA’s sorting equipment for commercial purposes.
Sorting plastic waste into polymer types is the first of three vital steps needed to close the loop on PP and create a global low carbon economy. The next step requires splitting the plastic packaging into food and non-food fractions. The final step involves NEXTLOOPP’s patented decontamination process, PPristineTM , which unlocks the markets to food packaging. Recycling 63,000 tonnes of PP per annum would save a minimum estimated 105,600 tonnes in CO2 emissions in the UK each year.
“During recent trials held at our TOMRA Test Centre we achieved very promising results on all Polypropylene 3D samples in all test runs with state-of-the-art NIR/VIS technology. We exceeded the required 95% purity for food-grade in each test run. The next important milestones will be a field demonstration as well as demonstrating chemical compliance with food-grade regulation” said Ralph Uepping, Technical Director at TOMRA.
Professor Edward Kosior, founder of Nextek, believes the NEXTLOOPP project is the catalyst to transform current FGrPP recycling and become the next food-grade recycling success story. PET was first and now it’s the turn of PP.
About Nextek Ltd
Nextek is a global sustainability consultancy that provides strategic advice to regional and multi-national organisations and recycling companies. Launched in 2004, Nextek researches and develops innovative strategies and processes within the recycling ecosystem – from designing recycling plants to developing ground-breaking projects for governments and major organisations. Nextek launched NEXTLOOPP, a two-year 37-strong project, to close the loop on food-grade recycled Polypropylene (rPP). This project incorporates unique technological breakthroughs that include innovative sorting and cutting-edge decontamination technologies.
About Tomra
TOMRA is a Norwegian multinational corporation that manufactures collection and sorting products, such as reverse vending machines for the food, recycling and mining industries. TOMRA is the market leader in its industry with over 100,000 installations in 80+ markets worldwide. Its Recycling Division has pioneered the automation of waste sorting.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005464/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
